{"type":"trials","record":{"id":41947,"source_id":"clinicaltrials-gov","external_id":"NCT06572553","title":"Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients","brief_summary":"The goal of this clinical trial is to learn if drug Faricimab works to treat nAMD, DME or RVO in adults. It will also learn about the safety of drug Faricimab. The main questions it aims to answer are: Does drug Faricimab can improve the best-corrected visual acuity of participants? What medical problems do participants have when inject drug Faricimab? Participants will inject drug Faricimab every month for 3 months. Visit the clinic once every 2 weeks for checkups.","overall_status":"Unknown","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","enrollment":30,"countries":["China"],"start_date":"2024-03-01","completion_date":"2024-08-31","last_update_date":"2024-08-27","source_url":"https://clinicaltrials.gov/study/NCT06572553","editorial_summary":"A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Second Affiliated Hospital, Zhejiang University, School of Medicine","interventions":["Faricimab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best Corrected Visual Acuity (BCVA) — through study completion, an average of 3 months.","central retinal thickness (CRT) — through study completion, an average of 3 months.","Choroidal neovascularization (CNV) — through study completion, an average of 3 months."],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Diabetic Macular Edema","Retinal Vein Occlusion","Faricimab"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06572553","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-03-01 to 2024-08-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.897Z","intervention":["Faricimab"],"participants":30,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2, PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best Corrected Visual Acuity (BCVA) — through study completion, an average of 3 months.","central retinal thickness (CRT) — through study completion, an average of 3 months.","Choroidal neovascularization (CNV) — through study completion, an average of 3 months."],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41947","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}